Bemarituzumab
From EverybodyWiki Bios & Wiki
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | FGFR2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}} |
Bemarituzumab (INN[1]) is a monoclonal antibody directed against fibroblast growth factor receptor 2b.[2][3] It is being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.
This drug is being developed by Five Prime Therapeutics, Zai Lab Limited. As of 2018[update], bemarituzumab is undergoing Phase III trials.[4][5]
References[edit]
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ↑ "Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers". Business Wire. 2018-09-10.
- ↑ "Bemarituzumab". National Cancer Institute.
- ↑ "Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - BioSpace".
- ↑ "Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers - BioSpace".
This monoclonal antibody–related article is a stub. You can help EverybodyWiki by expanding it. |
This antineoplastic or immunomodulatory drug article is a stub. You can help EverybodyWiki by expanding it. |
This article "Bemarituzumab" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Bemarituzumab. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.